Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference

About Globe Newswire

Nasdaq Globenewswire on NEWSTAGE
View all posts by Globe Newswire →

Leave a Reply

Your email address will not be published. Required fields are marked *